Bisoprolol and nebivolol are highly selective β1-adrenoceptor antagonists, with clinical
indications in many countries within the management of heart failure with reduced left …

Beta blockers have been used in the treatment of cardiovascular conditions for decades.
Despite a long history and status as a guideline-recommended treatment option for …

Endothelial dysfunction is a systemic pathological state of the endothelium characterized by
a reduction in the bioavailability of vasodilators, essentially nitric oxide, leading to impaired …

Nebivolol (Bystolic®) is a cardioselective beta 1 (β1)‐adrenergic receptor blocker with
endothelium‐dependent vasodilating properties. The endothelium‐dependent relaxation …

Objectives: β-Blockers increase variability in systolic blood pressure (SBP), which probably
explains their lesser effectiveness in preventing stroke vs myocardial infarction compared …

This MiniReview reports the current knowledge about the treatment of arterial hypertension
with the third‐generation beta‐adrenoceptor antagonist (BAA) nebivolol. Furthermore, it …

Hypertension is one of the leading risk factors for morbidity and mortality in patients with
cardiovascular and cerebrovascular diseases and renal impairment. It also leads to target …

β-blockers are among the most widely used drugs in the prevention and treatment of
cardiovascular disease, although they are associated with increased peripheral resistance …

Beta-blockers are commonly used medications, and they have been traditionally considered
“cardioprotective.” Their clinical use appears to be more widespread than the available …

Abstract β-adrenergic blocking agents, a pharmacologically diverse class of cardiovascular
medications, are recommended as first-line treatment for patients with hypertension and …